Product information

SPIOLTO® RESPIMAT® is a once daily long-acting LAMA/LABA therapy of tiotropium 5 mcg (LAMA) and olodaterol 5 mcg (LABA), delivered via RESPIMAT®. It is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). SPIOLTO® RESPIMAT® is administered as 2 puffs, once daily.1

Summary of Product Characteristics

Access the full SPIOLTO® RESPIMAT® Summary of Product Characteristics

Read more >

Efficacy

SPIOLTO® RESPIMAT® has efficacy across major components of COPD, with the greatest improvement seen in GOLD 2 and maintenance naïve patients.*2-5 SPIOLTO® RESPIMAT® significantly improves lung function, breathlessness and quality of life compared to monotherapies and placebo.2,3

Please click on the link below to read more:

RESPIMAT®

The RESPIMAT® unique mist is an innovative technology which sets it apart from other inhalers on the market. RESPIMAT® delivers medication actively, independent from patients’ inhalation force.6,7

Read more >

Safety

SPIOLTO® RESPIMAT® (tiotropium/olodaterol) has a comparable adverse event profile to the component monotherapies with a safety and tolerability profile established in patients treated for up to 52 weeks.1

Read more >

Dosing & administration

The recommended dose of SPIOLTO® RESPIMAT® is 5mcg tiotropium and 5mcg olodaterol, taken as 2 puffs once daily, at the same time each day. The dose is delivered via the SPIOLTO® RESPIMAT® soft mist inhaler device.1

Read more >

Mechanism of action

The active ingredients in SPIOLTO® RESPIMAT® are tiotropium, a long acting muscarinic receptor antagonist (LAMA) and olodaterol, a long acting beta2-adrenergic agonist (LABA). Together the LAMA/LABA combination provide additive bronchodilation due to their different modes of action and different locations of the target receptors in the lungs.1

Read more >

*without previous maintenance LAMA or LABA therapy.

RESPIMAT® delivers a metered dose of medication in a mist at the push of a button not requiring the force from the patient's inhalation.

References

  1. SPIOLTO® RESPIMAT® Summary of Product Characteristics February 2017.
  2. Buhl R, et al. Eur Respir J. 2015;45:969-979.
  3. Singh D, et al. Respir Med. 2015;109:1312-1319.
  4. Singh D, et al. Respir Res. 2016;17:73.
  5. Ferguson GT, et al. Adv Ther 2015 ; 32 : 523-536.
  6. Zierenberg B. J Aerosol Med. 1999;12(suppl 1 ):519-524.
  7. Dalby R, et al. Int J Pharm. 2004;283:1-9.